| 4.9 0.02 (0.41%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.49 | 1-year : | 15.18 |
| Resists | First : | 9.84 | Second : | 13 |
| Pivot price | 5.86  |
|||
| Supports | First : | 4.73 | Second : | 3.94 |
| MAs | MA(5) : | 5.11 |
MA(20) : | 7.52 |
| MA(100) : | 11.54 |
MA(250) : | 11.29 |
|
| MACD | MACD : | -2  |
Signal : | -2 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 5.2 |
| RSI | RSI(14): 24.4 |
|||
| 52-week | High : | 17.94 | Low : | 4.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AARD ] has closed above bottom band by 36.6%. Bollinger Bands are 47.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.99 - 5.02 | 5.02 - 5.04 |
| Low: | 4.73 - 4.76 | 4.76 - 4.8 |
| Close: | 4.85 - 4.9 | 4.9 - 4.95 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Wed, 18 Mar 2026
Aardvark Therapeutics, Inc. (AARD) - MSN
Sat, 07 Mar 2026
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Wed, 04 Mar 2026
AARD - Aardvark Therapeutics Latest Stock News & Market Updates - Stock Titan
Mon, 02 Mar 2026
Aardvark Therapeutics (NASDAQ:AARD) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Fri, 13 Feb 2026
New Aardvark Therapeutics hires get four-year stock option packages - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 59.2 (%) |
| Shares Short | 1,880 (K) |
| Shares Short P.Month | 1,620 (K) |
| EPS | -2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 0.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|